Quantcast

Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.

Research paper by Daniela D Saggioro, Maria Pia MP Rigobello, Lucia L Paloschi, Alessandra A Folda, Stephen A SA Moggach, Simon S Parsons, Luca L Ronconi, Dolores D Fregona, Alberto A Bindoli

Indexed on: 27 Oct '07Published on: 27 Oct '07Published in: Chemistry & Biology



Abstract

Although gold compounds are now recognized as promising anticancer agents, so far only gold(I) derivatives have been investigated for this purpose, whereas the use of gold(III) complexes has been hampered by their poor stability under physiological conditions. We have therefore carried out studies on selected gold(III) anticancer agents, showing enhanced stability due to the presence of chelating dithiocarbamato ligands. We found that they induce cancer cell death through both apoptotic and nonapoptotic mechanisms. They also inhibit thioredoxin reductase activity, generate free radicals, modify some mitochondrial functions, and increase ERK1/2 phosphorylation. Based on our results, we propose and discuss a working model suggesting that deregulation of the thioredoxin reductase/thioredoxin redox system is a major mechanism involved in the anticancer activity of the investigated gold(III)-dithiocarbamato complexes.